Drugs and Druggists' Sundries Merchant Wholesalers (NAICS 424210)

A Histometrics industry primer for public- and private-market investors

1. Overview

This is the plumbing of the U.S. medicine supply chain: the wholesalers that buy prescription drugs, generics, vaccines, and related health-and-beauty goods from manufacturers and deliver them to the roughly 60,000-plus pharmacies, hospitals, clinics, and doctors' offices that dispense them. Almost every prescription filled in America passes through one of these companies, usually within a day of being ordered.

Why an investor cares: it is a genuine oligopoly. Three firms — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — handle more than 90% of U.S. drug distribution by revenue [1]. FTC workshop data from 2017 showed combined shares of roughly 85% at that time, with McKesson at 32.7%, AmerisourceBergen at 31.6%, and Cardinal at 20.7% [2]. They run enormous, low-margin, high-velocity logistics networks, and they sit on one of the steadiest demand curves in the economy (sick and aging people need medicine regardless of the business cycle). It is a defensive, volume-driven business, not a high-growth one.

• Public route: the "Big Three" are all large-cap listed companies — buy the stocks directly, or hold them through a broad health-care or index fund. There is no pure-play distribution ETF, and there are essentially no small public players.
• Private route: a long tail of regional and independent wholesalers (many family-owned or cooperatively owned) and manufacturer-owned distributors. Private-equity money in this space mostly targets the downstream businesses distributors are buying into — specialty pharmacy and physician practices — rather than core wholesaling.

2. What it is and how it's structured

NAICS 424210 covers merchant wholesalers of biological and medical products, pharmaceuticals (tablets, capsules, vials, ointments, solutions), vaccines and blood derivatives, in-vitro diagnostics, botanicals, plus "druggists' sundries" — vitamins, supplements, cosmetics, toiletries, and first-aid goods [3]. "Merchant wholesaler" means the firm takes ownership of the goods (buys and resells at its own risk), as opposed to a broker or agent that never holds title. Commission-based wholesale agents and brokers generally fall in NAICS 425 [4].

What it excludes (adjacent codes):

• 423450 — Medical, Dental, and Hospital Equipment and Supplies wholesalers (surgical, dental, and hospital equipment is here, not 424210) [3].
• 446110 / 456110 — retail pharmacies and drug stores (the dispensers, not the wholesalers).
• 325412 — pharmaceutical manufacturing (making the drug, not moving it).
• Note that large integrated retailers and pharmacy-benefit managers (Walmart, CVS, Kroger) self-distribute a share of their own volume through captive networks, and some specialty and limited-distribution drugs ship manufacturer-direct or through specialty pharmacies. That volume can land in retail or manufacturing statistics rather than 424210 — so this code does not capture 100% of the medicine flowing through the country.

Operating model: A traditional pharmaceutical distributor purchases products from manufacturers, takes title and credit risk, holds inventory in highly automated distribution centers, and delivers mixed orders to retail chains, independent pharmacies, hospitals, health systems, long-term-care facilities, and physician practices. The operating value proposition is aggregation: a pharmacy can place one order covering products from hundreds of manufacturers rather than maintain separate procurement, credit, returns, and data connections with each supplier. Distributors also provide automated replenishment, inventory forecasting, controlled-substance monitoring, chargeback administration, returns, cold-chain handling, product serialization, reimbursement tools, and sometimes pharmacy buying groups or physician-practice services. McKesson's U.S. network had 27 distribution centers, including two redistribution centers, in fiscal 2026 [5].

The Healthcare Distribution Alliance describes distributors as the supply-chain participant taking legal ownership, physical possession, and financial risk in medicines. Its 2026 industry description says member distributors connect roughly 1,400 manufacturers with 450,000 pharmacies, providers, and other sites of care and deliver more than 10 million medicines, vaccines, and other healthcare products daily [6].

Ownership mix: dominated by publicly traded corporations at the top (the Big Three), with a competitive fringe of privately held regional distributors, buying cooperatives serving independent pharmacies, and manufacturer-owned distributors (for example Anda, owned by generics maker Teva). Unlike many wholesale trades, this is not a cottage industry of tiny operators — scale is the whole game.

3. How big it is

Federal statistics (our ground-truth figures):

Census 2023 data for NAICS 4242 reports 9,689 employer and nonemployer firms combined, with $1.253 trillion of sales; of these, 7,189 were employer firms accounting for $1.2529 trillion, while 2,500 nonemployers generated only $395.3 million of receipts — showing a very long tail by firm count but an almost entirely employer-firm revenue base [10].

Two honest caveats on these numbers:

Receipts are gross flow-through, not value added. That ~$1.28 trillion is essentially the cost of the medicine passing through, booked as revenue. The industry keeps only pennies on each dollar (see Section 5), so this figure vastly overstates the economic value the sector actually captures. The Census sales figure should not be confused with retail prescription-drug spending (CMS measured $467.0 billion in 2024 [11]) or with prescription sales through traditional distributors (HDA measured $666 billion in 2022 [12]). These figures use different scopes and valuation points.

Federal concentration looks milder than the industry does. The Census CR4 of 50.3% and HHI of 805.7 (a level the antitrust agencies technically call "unconcentrated," below 1,500) sit oddly against the widely cited "90%-plus for the top three" [1]. Both are correct at different scopes. Analysts measure the narrow prescription-drug-distribution market, which the Big Three do dominate; the Census measures every firm booking receipts under 424210 — including a long tail of generic, cosmetic, supplement, and sundry wholesaling, and excluding the medical-surgical, services, and international revenue the Big Three report elsewhere. Read the federal figures as the honest floor on measured concentration, and the ~90% as the reality of the core drug-distribution channel.

This industry is not undercounted the way trades full of sole proprietors are — big firms dominate, and the government captures them well. If anything, the receipts figure over-states, not under-states, the sector's true economic weight.

4. The investable universe

Public pure-plays are limited to three names — but they are giants. (Fiscal years differ: McKesson ends in March, Cardinal in June, Cencora in September.)

These are low-yield, buyback-heavy stocks, not income plays: dividend yields sit under ~1% (McKesson ~0.3%, Cardinal ~0.9%) [14]. Returns have come mostly from steady operating-income growth and share repurchases.

Customer concentration is substantial. McKesson reported that its ten largest customers accounted for approximately 73% of fiscal 2026 consolidated revenue; CVS Health alone accounted for approximately 24%, and the next two customers for 11% and 10%. Its ten largest suppliers represented approximately 71% of purchases [5]. Cardinal reported CVS Health at 30% of fiscal 2025 revenue, following the expiration of its OptumRx distribution contracts [17]. Scale does not eliminate bargaining risk: very large pharmacies, PBMs, group-purchasing organizations, and manufacturers can renegotiate or move contracts large enough to affect an entire distributor's results.

Adjacent public names (not pure drug distribution but overlapping): Henry Schein (HSIC) and Patterson Companies (PDCO) distribute dental, medical, and animal-health products; both sit largely in code 423450, not 424210.

Major private and other owners:

• Regional / independent wholesalers: Morris & Dickson (Shreveport, LA — the largest independent, serving ~17 southeastern states) [18]; Smith Drug (a J M Smith company); Value Drug; Dakota Drug; Mutual Drug; Prescription Supply. Many are private or cooperatively owned and serve independent pharmacies the Big Three under-serve. Note that Morris & Dickson reached a DEA settlement in 2024 following admitted failures involving thousands of unusually large opioid orders [19].
• Manufacturer-owned: Anda (owned by Teva), a generics-focused distributor.
• Buying groups / cooperatives that aggregate independent-pharmacy purchasing power.

If you want direct exposure, the three large-caps are effectively the only liquid options; everything else is private or a small slice of a diversified distributor.

5. How the money works

This is a razor-thin-margin, high-velocity business. Revenue is a poor guide to profit because most of it is pass-through drug cost. Operating margins run around 1–2%, on gross margins in the low-single-digits (roughly 3.5%) [1][20]. HDA's survey of large traditional distributors reported a 0.4% after-tax net margin for the 2022 operating year [12]. Public-company segment results illustrate the narrow spread: McKesson's North American Pharmaceutical segment generated $336.7 billion of fiscal 2026 revenue and $3.658 billion of segment operating profit, a 1.09% margin [5]; Cencora's U.S. Healthcare Solutions segment generated $291.0 billion of fiscal 2025 revenue and $3.575 billion of operating income, approximately 1.23% [21]; Cardinal Health's Pharmaceutical and Specialty Solutions segment produced $204.6 billion of fiscal 2025 revenue and $2.258 billion of segment profit, approximately 1.10% [17].

Owners make money on scale, logistics efficiency, product mix, and working-capital float — not on markup. The metrics that matter are gross profit, operating-income growth, generic/specialty mix, cash-conversion cycle, and return on invested capital (which is high precisely because the business is asset-light relative to its enormous revenue). HDA reported inventory held for an average of 24 days, automated methods in use at 66% of surveyed distributors, and nearly half of invoice lines picked automatically [12].

There are two profit pools:

1. Buy-side (from manufacturers). Brand-drug makers pay distributors distribution-service fees, often set as a percentage of the drug's list price (wholesale acquisition cost). Because the fee is tied to list price, rising branded prices historically lifted distributor income — an economic quirk now under political pressure.

2. Sell-side (from customers), driven by generics. This is the real engine. Against a fragmented field of generic manufacturers, the giant distributors have enormous buying power and capture a much wider spread on generics than on brands. The tell: generics and biosimilars were only about 15% of distribution revenue but roughly 77% of gross profit in 2022 [22]. To press that advantage, each of the Big Three runs a generic-sourcing joint venture with a large customer (for example, Red Oak Sourcing with CVS, ClarusONE with Walmart) to negotiate the lowest possible generic costs.

Additional levers:

• Working-capital float. Distributors typically collect from customers faster than they pay manufacturers and earn prompt-pay discounts, generating cash and (when list prices rise) inventory-appreciation gains. McKesson recorded a $210 million LIFO credit in fiscal 2026 after an $82 million LIFO charge in fiscal 2025, primarily because brand deflation replaced brand inflation [5].
• Specialty and buy-and-bill. High-value, cold-chain, high-touch distribution of oncology, autoimmune, and other specialty drugs to physician practices and hospitals — the fastest-growing, higher-service slice.
• Services and vertical integration. Group purchasing organizations (GPOs), third-party logistics, patient-support hubs, data, and increasingly owning the physician practices themselves (see Section 8).

6. What drives demand

• Aggregate drug spending and prescription volume. U.S. drug expenditures rose ~10.2% to about $805.9 billion in 2024, driven mainly by utilization (more prescriptions) rather than price [23]. CMS measured retail prescription-drug spending specifically at $467.0 billion in 2024, up 7.9%, and projects it to grow an average 5.7% annually over 2025–2034, the fastest growth among its major health-spending categories [11]. Volume is what distributors get paid to move.
• Aging population and chronic disease. Americans 65-plus are projected to grow from ~58 million (2022) toward ~82 million by 2050 [24] — a structural tailwind for medication demand.
• The GLP-1 boom. Weight-loss and diabetes drugs (GLP-1 receptor agonists) generated roughly $132 billion in 2025 sales, up ~33% year over year, and are now the single largest and fastest-growing drug category [25]. Their sheer volume flows straight through distributors and has been a named growth driver in recent results [15]. However, that distinction is important for economics: Cardinal reported that growing GLP-1 sales significantly increased revenue during the six months ended December 2025 but did not meaningfully contribute to segment profit [26]. Investors should therefore focus on segment profit and mix rather than treating gross GLP-1 sales as economic output.
• Specialty and biologics. Specialty drugs are now more than half of total drug spend [25]. HDA, citing IQVIA, reported U.S. specialty-medicine sales of $417 billion in 2024, up 12%, with immunology and oncology producing 70% of the year's growth [27]. This favors distributors with cold-chain infrastructure, limited-distribution access, oncology relationships, and commercialization services.
• Generic and biosimilar launches. Each patent cliff converts a brand into higher-margin generic/biosimilar volume — margin-accretive for distributors. HDA reported biosimilars rising from 0.7% to 3.9% of surveyed traditional-distributor sales between the 2021 and 2022 operating years [12].
• Vaccines and seasonal demand (flu, plus episodic events like COVID) add lumpy volume.

7. Regulation

Drug distribution is one of the most heavily regulated links in health care:

• DEA (controlled substances). Distributors must register with the Drug Enforcement Administration, respect production quotas, and run suspicious-order-monitoring and anti-diversion programs — the compliance regime that opioids put under a microscope.
• DSCSA (Drug Supply Chain Security Act, 2013). A 10-year build-out of electronic, package-level "track-and-trace" so any prescription drug can be traced through the supply chain. FDA enforcement of the final requirements began in 2025, with the wholesaler deadline on August 27, 2025 [28]. FDA's temporary exemption for eligible wholesale distributors ran only through that date, making serialization, data interoperability, and exception management ongoing compliance obligations [29][30]. Non-compliance can mean warning letters, fines, or license suspension — an existential compliance burden that also reinforces the incumbents' scale advantage.
• FDA oversight of drug handling, storage, and returns. Prescription-drug wholesalers must hold valid state licenses where required and report licensure to FDA [31].
• State boards of pharmacy license every wholesale distributor state-by-state; industry accreditation (through the National Association of Boards of Pharmacy) is a de facto requirement.
• Opioid-settlement obligations (Section 9) include a national clearinghouse for controlled-substance distribution data and mandated anti-diversion changes [32].
• Drug-pricing reform. The Inflation Reduction Act's Medicare price negotiation and Part D redesign, plus broader list-price scrutiny, pressure the branded fee-for-service model that ties distributor income to list prices.
• Antitrust / FTC attention has shifted to the distributors' vertical push into physician practices.

8. Competitive dynamics and consolidation

The horizontal consolidation is essentially finished — three firms, ~90%-plus of the channel [1]. Barriers to entry are formidable: national logistics networks, state-by-state licensing, DSCSA compliance systems, and generic-sourcing scale. The laborious digital traceability regime may disadvantage undercapitalized regional firms, while national players face the opposite problem: their scale attracts antitrust scrutiny and makes a single large-customer contract or compliance failure material. The interesting action now is customer power and vertical integration.

• Customer concentration cuts both ways. The distributors' biggest customers are themselves giants — CVS, Walgreens, Walmart, and PBMs like OptumRx — with the leverage to squeeze already-thin margins. A single contract can move ~$40 billion of revenue: Cardinal's fiscal-2025 revenue dipped because the OptumRx contract expired, while McKesson won large OptumRx volume [13][16].
• Vertical integration downstream. The Big Three have spent more than $16 billion acquiring management-services organizations (MSOs) that run physician practices in oncology, gastroenterology, urology, and ophthalmology [33]. Examples: McKesson's moves around US Oncology, OneOncology, and community-oncology practices; Cardinal Health's majority stakes in GI Alliance and Solaris Health and its ION oncology platform [33][34]. Owning the practice lets a distributor redirect that practice's drug purchasing, GPO, and services to itself and away from rivals — a new front of competition for the lucrative buy-and-bill specialty channel.
• Portfolio focus. McKesson intends to spin off its Medical-Surgical Solutions segment (targeted H2 2027) to concentrate on pharmaceutical distribution and oncology services [13].

9. Risks

• Litigation tail. In 2021 McKesson, Cardinal, and AmerisourceBergen (now Cencora) agreed to pay up to ~$21 billion over 18 years to settle opioid claims (part of a ~$26 billion deal that also included Johnson & Johnson) [32][35]. The core settlement is being paid, but the multi-year cash drain and the risk of new litigation themes remain.
• Pricing reform. Because branded fee income is tied to list prices, IRA price negotiation, Part D redesign, and any move to flatten list prices compress a real profit lever and shrink inventory-appreciation gains.
• Customer concentration / contract renewals. Losing or winning one mega-customer swings tens of billions in revenue and meaningful profit.
• Thin margins, low pricing power. At ~1–2% operating margins, small cost, mix, or contract shifts hit the bottom line hard. Working-capital funding, interest rates, manufacturer payment terms, customer credit, and pharmacy bankruptcies can move earnings and cash flow even when prescription utilization remains stable.
• Antitrust scrutiny of the vertical move into physician practices.
• Cybersecurity and supply-chain shocks. Concentrated, digital-dependent logistics are a target (Cencora disclosed a data breach in 2024), and drug shortages disrupt the flow that generates fees.
• Disintermediation risk (longer-term). Manufacturer-direct models (e.g., drugmakers selling straight to patients), cost-plus pharmacies, and Amazon Pharmacy could reroute some volume — though nearly all still rely on the Big Three's physical logistics today. The need for regulated physical handling, financing, returns, and package-level traceability makes complete disintermediation difficult.

10. How to invest and the outlook

Public routes. The cleanest exposure is the three large-caps — McKesson (MCK), Cencora (COR), and Cardinal Health (CAH) — all on the NYSE. They are defensive, volume-driven compounders: low dividend yields (under ~1%) [14] but consistent operating-income growth and heavy buybacks. Broad health-care sector funds and total-market index funds already hold them; there is no dedicated drug-distribution ETF. For a wider distribution tilt (dental/medical/animal health), Henry Schein and Patterson are adjacent, though they sit largely outside 424210. Note that segment disclosures require adjustment for physician-practice, technology, international, and medical-supply operations; none of the three is a pure 424210 security.

Private routes. Direct ownership means the regional and independent wholesalers — Morris & Dickson, Smith Drug, Value Drug, Dakota Drug, Mutual Drug and peers — most of which are private or cooperatively owned and rarely change hands [18]. Private-market exposure is also available through specialty distributors, veterinary or consumer-health wholesalers, cold-chain and reverse-logistics providers, and technology businesses supporting DSCSA traceability or inventory management. Diligence must concentrate on state licensing, DEA registrations, suspicious-order systems, manufacturer authorization, serialization capability, customer concentration, inventory ownership, return rights, and working-capital financing. Note that private-capital interest has migrated to the downstream assets the distributors themselves are buying — specialty pharmacy and physician-practice platforms (oncology, GI, urology) — which is where the growth and the deal flow now sit.

Near-term drivers (forward-looking judgment). The tailwinds look durable: sustained GLP-1 and specialty volume, a biosimilar/generic-launch wave that is margin-accretive, an aging population, and the payoff (or antitrust pushback) from vertical integration into physician practices. The watch-items are drug-pricing reform eroding branded fee income, mega-customer contract renewals, opioid-settlement cash outflows, and cyber/operational risk. On balance this is a steady, cash-generative, defensively positioned industry — prized for reliability and reinvestment rather than growth or yield, and unusually insulated by scale, licensing, and compliance moats that make new entry nearly impossible.

---

Sources

1. IntuitionLabs. "US Drug Wholesalers: How McKesson, Cencora & Cardinal Control 90%+ of Distribution." 2025. https://intuitionlabs.ai/articles/drug-wholesaler-market-concentration
2. Federal Trade Commission. "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics" workshop slides, page 100 (2017 market shares). 2017. https://www.ftc.gov/system/files/documents/public_events/1255653/understanding_competition_in_prescription_drug_markets_workshop_slides_11-8-17.pdf
3. NAICS Association. "NAICS Code 424210 — Drugs and Druggists' Sundries Merchant Wholesalers" (definition and cross-references). 2022. https://www.naics.com/naics-code-description/?code=424210
4. U.S. Census Bureau. NAICS 424210 profile (industry boundary and adjacent codes). 2022. https://data.census.gov/profile/424210_-_Drugs_and_Druggists%27_Sundries_Merchant_Wholesalers?codeset=naics~424210
5. McKesson Corporation. Fiscal 2026 Form 10-K (distribution network, customer concentration, LIFO accounting). 2026. https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
6. Healthcare Distribution Alliance. "Understanding Healthcare Distributors and Their Role." 2026. https://www.hda.org/perspectives/2026/02/understanding-healthcare-distributors-and-their-role/
7. U.S. Census Bureau. 2022 Economic Census, Concentration & Selected Statistics (NAICS 424210): receipts, firm count, CR4/CR8/CR20/CR50, HHI. 2022. https://www.census.gov/programs-surveys/economic-census.html
8. U.S. Census Bureau. County Business Patterns, 2023 (NAICS 424210): establishments, employment, payroll. 2023. https://www.census.gov/programs-surveys/cbp.html
9. U.S. Small Business Administration. Table of Small Business Size Standards (NAICS 424210 = 250 employees). 2023. https://www.sba.gov/document/support-table-size-standards
10. U.S. Census Bureau. 2023 Nonemployer Statistics by Demographics (NAICS 4242): employer and nonemployer firm counts and sales. 2023. https://data.census.gov/table/ABSNESD2023.AB00MYNESD01C?codeset=naics~4242&g=010XX00US
11. Centers for Medicare & Medicaid Services. National Health Expenditure Fact Sheet (retail prescription drug spending $467.0B in 2024; 5.7% projected annual growth 2025–2034). 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
12. Healthcare Distribution Alliance. 2022 Operating-Year Factbook Summary (margins, inventory days, automation, biosimilar share). 2023. https://hda.org/newsroom/2023/hda-factbook-rx-sales-through-traditional-healthcare-distributors-increase/
13. McKesson Corporation. "McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions." 2025. https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-reports-fiscal-2025-fourth-quarter-and-full-year-results/
14. American Association of Individual Investors (AAII). "Which Is a Better Investment, Cardinal Health Inc or McKesson Corp Stock?" (market caps and dividend yields, early 2026). 2026. https://www.aaii.com/investingideas/article/25359-which-is-a-better-investment-cardinal-health-inc-or-mckesson-corp-stock
15. Cencora, Inc. "Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results." 2025. https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results/default.aspx
16. Cardinal Health, Inc. Fiscal 2025 fourth-quarter and full-year results (Form 8-K) and FY25 Annual Report. 2025. https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-FY25-annual-report.pdf
17. Cardinal Health, Inc. Fiscal 2025 Form 10-K (CVS concentration, segment results). 2025. https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm
18. DrugZone / Morris & Dickson. "Top Pharmaceutical Distributors in the USA" and Morris & Dickson company profile (regional/independent distributors). 2025. https://www.drugzone.com/blog/top-7-pharmaceutical-distributors-in-the-usa
19. Drug Enforcement Administration. "DEA Announces Settlement with Morris & Dickson Co., LLC." 2024. https://www.dea.gov/press-releases/2024/02/07/dea-announces-settlement-morris-dickson-co-llc
20. FinancialContent. "McKesson (MCK): A Deep-Dive into the Backbone of the Healthcare Supply Chain" (operating and gross margin figures). 2026. https://markets.financialcontent.com/stocks/article/finterra-2026-3-18-mckesson-mck-a-deep-dive-into-the-backbone-of-the-healthcare-supply-chain
21. Cencora, Inc. Fiscal 2025 results filed with the SEC (U.S. Healthcare Solutions segment). 2025. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000128/exhibit991-q42025.htm
22. Drug Channels (Adam J. Fein). "How the Biosimilar Boom Boosts Drug Wholesalers' Profits" (generic share of revenue vs. gross profit). 2022. https://www.drugchannels.net/2022/10/how-biosimilar-boom-boosts-drug.html
23. ASHP / American Journal of Health-System Pharmacy. "National trends in prescription drug expenditures and projections" (U.S. drug spending +10.2% to $805.9B in 2024). 2024–2025. https://news.ashp.org/news/ashp-news/2025/04/24/us-drug-spending-up-10-in-2024-with-weight-loss-drugs-remaining-top-driver
24. Grand View Research / U.S. Census Bureau projections. U.S. population 65+ growth ~58M (2022) to ~82M (2050). 2024. https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
25. Towards Healthcare. "GLP-1 Drugs Market Sizing" (GLP-1 ~$132B 2025 sales; specialty share of drug spend). 2025. https://www.towardshealthcare.com/insights/glp1-drugs-market-sizing
26. Cardinal Health, Inc. Form 10-Q (GLP-1 revenue vs. profit impact, six months ended December 2025). 2026. https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm
27. Healthcare Distribution Alliance. "Specialty Distributors: Meeting the Challenges of a Growing Market" (IQVIA specialty-medicine sales $417B in 2024). 2025. https://hda.org/newsroom/2025/december/specialty-distributors-meeting-the-challenges-of-a-growing-market/
28. Körber Supply Chain. "DSCSA Enforcement has begun: What the May 27, 2025 deadline means" (wholesaler deadline August 27, 2025). 2025. https://koerber-supplychain.com/about-us/blog/dscsa-enforcement-has-begun/
29. U.S. Food and Drug Administration. DSCSA Exemption for Eligible Wholesale Distributors (temporary exemption through August 27, 2025). 2025. https://www.fda.gov/media/182584/download?attachment=
30. U.S. Food and Drug Administration. Drug Supply Chain Security Act (DSCSA) Overview. 2025. https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
31. U.S. Food and Drug Administration. "Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers." 2025. https://www.fda.gov/drugs/drug-supply-chain-integrity/check-licensure-wholesale-drug-distributors-and-third-party-logistics-providers
32. National Opioids Settlement. "Executive Summary" (distributor settlement terms and clearinghouse). 2021–2024. https://nationalopioidsettlement.com/executive-summary/
33. Drug Channels (Adam J. Fein). "The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers' Vertical Integration with Physician Practices" (>$16B MSO acquisitions). 2025. https://www.drugchannels.net/2025/10/the-future-of-buy-and-bill-market.html
34. VMG Health. "Strategic Consolidation in Oncology." 2025. https://vmghealth.com/insights/blog/strategic-consolidation-in-oncology/
35. CNBC. "Big 3 U.S. drug distributors, Johnson & Johnson reach landmark $26 billion opioid settlement." 2021. https://www.cnbc.com/2021/07/21/drug-distributors-jj-reach-landmark-26-billion-opioid-settlement-.html